Table 2: Patients with prostate adenocarcinoma and BRCA1/2 study.

Patient	Year of the study	Tumor	Tumor BRCA 1/2	Germline BRCA 1/2
1	2017	Prostate adenocarcinoma	NPV	NS
2	2018	Prostate adenocarcinoma	NPV	NS
3	2018	Prostate adenocarcinoma	NPV	NS
4	2018	Prostate adenocarcinoma	NPV	NS
5	2018	Prostate adenocarcinoma	BRCA2 mutation	Normal
6	2018	Prostate adenocarcinoma	BRCA2 mutation	BRCA2 mutation
7	2018	Prostate adenocarcinoma	NPV	NS
8	2018	Prostate adenocarcinoma	NPV	NS
9	2018	Prostate adenocarcinoma	NPV	NS

NPV: no pathogenic variants (when both genes are studied); Normal: no mutation (when only the pathogenic variant uncovered at the tumor is studied); NS: not studied.